Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Turning Point and Libtayo steal some pre-Asco thunder
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
